Press Release

Massive R&D Investments in Advanced Diagnosis & Treatment for Oncology to Boost the Ovarian Cancer Market

The Global Ovarian Cancer Market is expecting a double-digit CAGR during 2022-27, cites MarkNtel Advisors in their recent research report. The growing patient pool of ovarian cancer, i.e., leading to the mounting demand for accurate, reliable, & timely diagnoses to provide adequate treatments, is driving the global market. Besides, with the increasing public awareness about ovarian cancer being a prominent cause of death, governments of different countries are massively investing in R&D activities while imposing favorable norms for conducting clinical trials.

Moreover, governments are also investing in enhancing healthcare facilities to ensure the anytime availability of advanced equipment, drugs, & medical professionals to provide the required treatments to patients. Furthermore, as the leading players are actively participating in drug developments, the market is witnessing new progressions with time.

The results of novel MOA (Mechanism of Action) like checkpoint inhibitors are revolutionizing the treatment landscape for different cancers. Hence, these factors hint at remunerative opportunities for the market in the coming years, further states the research report, “Global Ovarian Cancer Market Analysis, 2022.”

Targeted Therapies to Generate Lucrative Prospects for the Ovarian Cancer Market through 2027

Doublet chemotherapy, i.e., Carboplatin & Paclitaxel, is the most common treatment for ovarian cancer. However, bevacizumab (Avastin) combined with chemotherapy has shown enhanced efficacy & OS (overall survival) rate. In addition to Bevacizumab, Olaparib, Rucaparib, & Niraparib are other targeted therapy drugs provided to patients with advanced ovarian cancer. These drugs that have revolutionized the treatment landscape for ovarian cancer are set to generate a pool of profitable opportunities for the leading players operating in the Global Ovarian Cancer Market through 2027.

With Significant Developments in the Healthcare Infrastructure, Asia-Pacific to Experience Fastest Market Growth

Several countries across Asia-Pacific are witnessing a rapidly & extensively rising population, coupled with a large number of ovarian cancer patients. As a result, there's a dire need for accurate & timely diagnosis and effective therapies for the early detection of disease, thereby driving the regional market.

Countries like China & India are actively participating in developing world-class healthcare infrastructure by investing massively in the construction of new hospitals, research centers, clinics, etc. Moreover, these countries are also procuring advanced diagnostic devices & drugs for ovarian cancer treatment, i.e., playing a prominent role in stimulating the overall growth of the Ovarian Cancer Market across Asia-pacific.

Competitive Landscape

The leading players in the Global Ovarian Cancer Market are AstraZeneca PLC., AbbVie Inc., Amgen Inc., Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC., Merck & Co., Inc., Novartis International AG, and Pfizer Inc.

Key Questions Answered in the Research Report

1. What are the current & future trends in the Global Ovarian Cancer Market?
2. How has the industry been evolving in terms of geography & product adoption?
3. How has the competition been shaping across various regions, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Ovarian Cancer Market?
5. What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Ovarian Cancer Market?

Market Segmentation:

1. By Diagnosis (Blood Tests, Pelvic Examination, Imaging, Biopsy)
2. By Cancer Type (Epithelial Tumor, Germ Cell Tumor, Stromal Tumor)
3. By Treatment (Surgery, Chemotherapy (Taxol (paclitaxel), Taxotere (docetaxel), Platinol (cisplatin), Paraplatin (carboplatin)), Targeted Therapy (Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib)), Others (Immunotherapy, Hormone Therapy, etc.))
4. By End-User (Hospitals, Specialty Cancer Centers, Others (Ambulatory Surgery Centers, etc.))
5. By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)
6. By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)